Samsung Biologics has signed a contract worth 111.2 billion won with an undisclosed U.S. pharmaceutical firm to provide ...

Korean contract development and manufacturing organizations (CDMOs) are set to engage with global drugmakers at the upcoming ...

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its ...

Samsung Biologics earns spot on Dow Jones Sustainability Index for fourth year Samsung Biologics maintains its position in ...

Biomedicines ("Generate") as part of its efforts to drive growth and innovation in the biopharmaceutical sector. The ...

The combined market capitalisation of Samsung Group's affiliates dropped about 23 per cent in 2024 due to the sluggish performance of its key affiliate Samsung Electronics, data showed on Sunday.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Samsung Biologics announced on the 10th that it has received certification as a health-friendly corporation in the '2024 Health-Friendly Corporation Certification Project' organized by the ...

Threading quality into every step: One-stop manufacturing at Samsung Biologics Samsung Biologics, a fully integrated CDMO, is dedicated to ensuring high-quality production through its ...

SEOUL, Dec. 30 (Korea Bizwire) — Samsung Group, South Korea’s largest conglomerate, has seen its market capitalization ...

Samsung invests in Generate to advance AI-driven protein therapeutics discovery: Incheon, South Korea Saturday, December 21, 2024, 17:00 Hrs [IST] Samsung announced that it has in ...